Evidence map›Paper›PMID 42170792›Full record

Observational studyCancer biology & medicine2026

Efficacy and safety of first-line osimertinib in Chinese patients with EGFR-mutated advanced non-small cell lung cancer: a prospective, multicenter, non-interventional study (FLOURISH).

Lisha Shen, Dongqing Lv, Ke-Jing Tang, Jun Zhao, Dan Zhu, Yanqiu Zhao, Ke Wang, Yan Wang, Zhigang Cai, Ligang Xing and 15 more

Abstract readMulticenter StudyObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Cancer biology & medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Lisha Shen *Department of Respiratory Disease, Thoracic Disease Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310058, China.
Dongqing Lv *Department of Respiratory Disease, Affiliated Taizhou Hospital of Zhejiang Province of Wenzhou Medical University, Taizhou 318000, China.
Ke-Jing Tang *Department of Respiratory Disease, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510080, China.
Jun ZhaoChangzhi People's Hospital Affiliated to Changzhi Medical College, Changzhi 046000, China.
Dan ZhuJinhua Municipal Central Hospital, Jinhua 321000, China.
Yanqiu ZhaoThe Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou 450008, China.
Ke WangWest China Hospital of Sichuan University, Chengdu 610041, China.
Yan WangTumor Hospital Affiliated to Harbin Medical University, Harbin 150081, China.
Zhigang CaiThe Second Hospital of Hebei Medical University, Shijiazhuang 050000, China.
Ligang XingShandong Cancer Hospital and Institute, Shandong First Medical University, Jinan 250014, China.
Ke XieSichuan Provincial People's Hospital, Chengdu 610072, China.
Jiuwei CuiThe First Hospital of Jilin University, Changchun 130021, China.
Lin MuHeping Hospital Affiliated to Changzhi Medical College, Changzhi 046000, China.
Chao CaoThe First Affiliated Hospital of Ningbo University, Ningbo 315010, China.
Liren DingThe Second Affiliated Hospital (Binjiang Campus), School of Medicine, Zhejiang University, Hangzhou 310022, China.
Peifeng ChenZhuji People's Hospital, Zhuji 311800, China.
Jun LiangPeking University International Hospital, Beijing 102206, China.
Yongmin DingShengzhou People's Hospital, Shengzhou 312400, China.
Liqin LuZhejiang Provincial People's Hospital, Hangzhou 310014, China.
Jiliang ZhangChengdu Seventh People's Hospital (Affiliated Cancer Hospital of Chengdu Medical College), Chengdu 610072, China.
Xinmin YuZhejiang Cancer Hospital, Hangzhou 310022, China.
Li ChenThe First Affiliated Hospital of Nanchang University, Nanchang 330006, China.
Jing ZhengDepartment of Respiratory Disease, Thoracic Disease Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310058, China.
Jianya ZhouDepartment of Respiratory Disease, Thoracic Disease Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310058, China.ORCID 0000-0001-8196-0166
Jianying ZhouDepartment of Respiratory Disease, Thoracic Disease Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310058, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveOsimertinib has demonstrated superior efficacy as a first-line treatment for epidermal growth factor receptor (

methodsThis prospective, multicenter, non-interventional study was conducted from July 27, 2020, to April 27, 2022. Treatment-naïve adults (≥18 years of age) with locally advanced or metastatic

resultsAmong 481 patients (median age 64.1 years; 62.2% women), the median follow-up was 31.3 months. The mTTD was 24.6 months (95% CI, 22.4-26.7), the median rwPFS was 19.4 months (95% CI, 16.2-20.4), and the mOS was 41.0 months [95% CI, 39.7 to not reached (NR)]. The mOS was 43.1 months (95% CI, 39.7 to NR) in FLAURA-eligible patients

conclusionsFirst-line osimertinib demonstrated robust effectiveness and manageable safety in real-world Chinese patients with

Indexed as

Antineoplastic AgentsCarcinoma, Non-Small-Cell LungLung NeoplasmsProtein Kinase InhibitorsAcrylamidesAdultAgedAged, 80 and overAniline CompoundsChinaEast Asian PeopleErbB ReceptorsFemaleHumansIndolesMaleAcrylamidesAniline CompoundsAntineoplastic AgentsEGFR protein, humanErbB ReceptorsIndolesosimertinibProtein Kinase InhibitorsPyrimidinesco-mutationsepidermal growth factor receptornon-small cell lung cancerOsimertinibreal-world

Identifiers

PMID42170792
PMCPMC13498878

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.